{Reference Type}: Journal Article
{Title}: Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
{Author}: Sun SS;Guo XD;Li WD;Chen JL;
{Journal}: World J Clin Cases
{Volume}: 12
{Issue}: 2
{Year}: 2024 Jan 16
{Factor}: 1.534
{DOI}: 10.12998/wjcc.v12.i2.285
{Abstract}: <B>BACKGROUND: </B>Recently, combination therapy has shown a better trend towards improved tumour response and survival outcomes than monotherapy in patients with hepatocellular carcinoma (HCC). However, research on triple therapy [lenvatinib + sintilimab + transarterial chemoembolization (TACE)] as a first-line treatment for advanced HCC is limited.<BR><B>OBJECTIVE: </B>To evaluate the safety and efficacy of triple therapy as a first-line treatment for advanced HCC.<BR><B>METHODS: </B>HCC patients with Barcelona Clinic Liver Cancer stage C treated with triple therapy were enrolled. All patients were treated with lenvatinib every day and sintilimab once every 3 wk. Moreover, TACE was performed every 4-6 wk if necessary. The primary outcome of the study was overall survival (OS). The secondary outcomes were the objective response rate (ORR), disease control rate (DCR), and incidence of adverse events.<BR><B>RESULTS: </B>Forty HCC patients who underwent triple therapy were retrospectively analysed from January 2019 to January 2022. With a median follow-up of 8.5 months, the 3-, 6-, and 12-mo OS rates were 100%, 88.5%, and 22.5%, respectively. The ORR and DCR were 45% and 90%, respectively. The median progressive free survival and median OS were not reached. Common complications were observed in 76% of the patients (grade 3, 15%; grade 4, 2.5%).<BR><B>CONCLUSIONS: </B>Combination therapy comprising lenvatinib, sintilimab and TACE achieved promising outcomes in advanced HCC patients and had manageable effects.